The researchers found that the coronavirus vaccines developed by biotech giant Pfizer and Moderna appear to protect against deadly Indian variants of the coronavirus from India.

The latest study was conducted at New York University’s Grossman School of Medicine and New York University’s Langone Center and is considered preliminary because it has not yet been published in a peer-reviewed journal.

According to laboratory experiments involving cell cultures, variants B.1.617 and B.1.618 were found to be partially resistant to antibodies obtained by the graft.

The researchers said there are strong reasons to believe that vaccinated people will continue to be protected from variants B.1.617 and B.1.618.

They added that vaccine antibodies are slightly weaker against variants, but not to the extent that this would significantly affect the protective capacity of vaccines.

The World Health Organization has previously reclassified the highly infectious variant of Covid triple mutants circulating in India as a “variable of interest”, suggesting it has become a global health threat.

Maria Van Kerkhove, WHO’s COVID-19 technical officer, said the variant known as B.1.617 spreads more easily in initial research than the parent virus, and there is some evidence that it may escape some protection … through vaccination …

“This is why we classify it as another type of global concern,” she said.

Kerkhov said: “While there is an increased transmissibility that has been demonstrated by some preliminary studies, we need more information about this viral variant in this lineage for all subspecies, so we need more sequencing and targeting sequences.”

The following two tabs change content below.


Please enter your comment!
Please enter your name here